Gangliosides as Signaling Regulators in Cancer.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
11 May 2021
Historique:
received: 18 04 2021
revised: 07 05 2021
accepted: 07 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 10 6 2021
Statut: epublish

Résumé

At the plasma membrane, gangliosides, a group of glycosphingolipids, are expressed along with glycosphingolipids, phospholipids, and cholesterol in so-called lipid rafts that interact with signaling receptors and related molecules. Most cancers present abnormalities in the intracellular signal transduction system involved in tumor growth, invasion, and metastasis. To date, the roles of gangliosides as regulators of signal transduction have been reported in several cancer types. Gangliosides can be expressed by the exogenous ganglioside addition, with their endogenous expression regulated at the enzymatic level by targeting specific glycosyltransferases. Accordingly, the relationship between changes in the composition of cell surface gangliosides and signal transduction has been investigated by controlling ganglioside expression. In cancer cells, several types of signaling molecules are positively or negatively regulated by ganglioside expression levels, promoting malignant properties. Moreover, antibodies against gangliosides have been shown to possess cytotoxic effects on ganglioside-expressing cancer cells. In the present review, we highlight the involvement of gangliosides in the regulation of cancer cell signaling, and we explore possible therapies targeting ganglioside-expressing cancer.

Identifiants

pubmed: 34064863
pii: ijms22105076
doi: 10.3390/ijms22105076
pmc: PMC8150402
pii:
doi:

Substances chimiques

Gangliosides 0
Glycosyltransferases EC 2.4.-

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

BMC Cancer. 2014 Apr 28;14:295
pubmed: 24773917
Cancer Sci. 2014 Jan;105(1):52-63
pubmed: 24372645
Front Cell Dev Biol. 2020 Feb 07;8:55
pubmed: 32117981
Clin Cancer Res. 2003 Nov 1;9(14):5214-20
pubmed: 14614001
Glycobiology. 2006 Jul;16(7):573-83
pubmed: 16574813
Am J Cancer Res. 2014 Nov 19;4(6):801-10
pubmed: 25520869
Cell Prolif. 2019 Jul;52(4):e12639
pubmed: 31127673
J Neurooncol. 2015 May;122(3):517-27
pubmed: 25800004
Science. 1997 Sep 12;277(5332):1652-5
pubmed: 9287216
Int J Cancer. 2001 Nov 1;94(3):328-34
pubmed: 11745410
Biochim Biophys Acta. 2016 Aug;1860(8):1753-63
pubmed: 27068854
Oncotarget. 2017 Jul 18;8(29):47454-47473
pubmed: 28537895
Cancer Sci. 2012 Sep;103(9):1656-64
pubmed: 22632091
Int J Biochem Cell Biol. 2013 Nov;45(11):2349-58
pubmed: 23968914
FEBS Lett. 2001 Sep 28;506(1):45-50
pubmed: 11591368
Curr Oncol. 2018 Jun;25(Suppl 1):S142-S150
pubmed: 29910657
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Diabetes. 2007 May;56(5):1341-9
pubmed: 17287460
Mol Cancer Ther. 2018 Dec;17(12):2689-2701
pubmed: 30237308
Immunotherapy. 2016 Sep;8(9):1097-117
pubmed: 27485082
In Vivo. 2014 Nov-Dec;28(6):1005-11
pubmed: 25398793
Pharmazie. 2018 Feb 1;73(2):80-86
pubmed: 29442009
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10718-23
pubmed: 12149448
Prog Mol Biol Transl Sci. 2018;156:83-120
pubmed: 29747825
J Biol Chem. 2002 Mar 29;277(13):11239-46
pubmed: 11782461
Cancer Sci. 2011 Dec;102(12):2157-63
pubmed: 21895875
Cancer Res. 2005 Nov 1;65(21):9868-75
pubmed: 16267010
Int J Mol Sci. 2019 Apr 12;20(8):
pubmed: 31013778
Cell Death Differ. 2012 Jan;19(1):170-9
pubmed: 21681193
Cancer. 2015 Mar 1;121(5):664-72
pubmed: 25336398
Oncoimmunology. 2015 Apr 2;4(8):e1023975
pubmed: 26405581
Glycobiology. 2012 Jun;22(6):806-16
pubmed: 22301273
J Biol Chem. 1986 Feb 15;261(5):2434-40
pubmed: 2418024
Eur J Cancer. 2009 Sep;45 Suppl 1:27-40
pubmed: 19775602
J Biol Chem. 2011 May 27;286(21):18526-37
pubmed: 21454696
J Natl Cancer Inst. 2000 Jun 7;92(11):912-7
pubmed: 10841826
Sci Rep. 2018 Feb 7;8(1):2561
pubmed: 29416099
Clin Cancer Res. 2000 Dec;6(12):4658-62
pubmed: 11156217
Urology. 2013 Jan;81(1):210.e11-5
pubmed: 23102779
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Mol Cell Biochem. 2013 Oct;382(1-2):83-92
pubmed: 23749170
Int J Oncol. 2018 Apr;52(4):1255-1266
pubmed: 29436609
Oncotarget. 2017 May 24;8(34):56758-56767
pubmed: 28915628
J Biol Chem. 2016 Oct 7;291(41):21424-21433
pubmed: 27539856
Curr Oncol Rep. 2018 Mar 23;20(3):29
pubmed: 29569208
Neuroscience. 2006 Sep 15;141(4):1925-33
pubmed: 16809005
Oncogene. 2015 Jun 4;34(23):2958-67
pubmed: 25109336
Cancers (Basel). 2020 Oct 14;12(10):
pubmed: 33066597
Oncotarget. 2015 Oct 13;6(31):31085-103
pubmed: 26393679
Adv Exp Med Biol. 1980;125:11
pubmed: 7361610
Int J Cancer. 2015 Oct 1;137(7):1560-73
pubmed: 25810027
Expert Opin Drug Deliv. 2007 Mar;4(2):175-86
pubmed: 17335414
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Sci Rep. 2019 Dec 18;9(1):19369
pubmed: 31852956
Pharmacol Ther. 2019 Jan;193:31-49
pubmed: 30121319
Mol Med Rep. 2015 Apr;11(4):2959-66
pubmed: 25503644
Acta Dermatovenerol Croat. 2019 Sep;27(3):163-168
pubmed: 31542060
J Cell Biochem. 2013 Jul;114(7):1616-24
pubmed: 23355442
Biochem Biophys Res Commun. 2007 Jun 22;358(1):226-32
pubmed: 17482563
Cell Prolif. 2002 Apr;35(2):105-15
pubmed: 11952645
World J Gastroenterol. 2001 Dec;7(6):816-20
pubmed: 11854908
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
N Engl J Med. 1988 Sep 1;319(9):525-32
pubmed: 2841597
Cancer Res. 2001 May 15;61(10):4244-52
pubmed: 11358851
Nat Med. 2011 Apr;17(4):500-3
pubmed: 21460848
Arq Neuropsiquiatr. 1997 Sep;55(3A):444-51
pubmed: 9629363
Cell Commun Signal. 2017 May 12;15(1):19
pubmed: 28499439
PLoS One. 2009;4(3):e4723
pubmed: 19305508
PLoS One. 2014 May 14;9(5):e92786
pubmed: 24829158
J Biol Chem. 2015 Jun 26;290(26):16043-58
pubmed: 25940087
Apoptosis. 2015 May;20(5):584-606
pubmed: 25702154
Proc Natl Acad Sci U S A. 2016 May 17;113(20):5592-7
pubmed: 27143722
Carbohydr Res. 2009 Aug 17;344(12):1479-86
pubmed: 19559406
Cell Immunol. 2018 Nov;333:46-57
pubmed: 29576316
J Biol Chem. 2012 Dec 14;287(51):42835-45
pubmed: 23139422
Int Immunol. 2021 Jan 1;33(1):7-15
pubmed: 32496557
Int J Oncol. 2015 Sep;47(3):1143-59
pubmed: 26134970
FASEB J. 2003 Jun;17(9):1162-4
pubmed: 12709413
Bull Exp Biol Med. 2019 Feb;166(4):541-547
pubmed: 30783840
Int J Mol Sci. 2016 Apr 30;17(5):
pubmed: 27144558
Int J Mol Sci. 2016 Oct 15;17(10):
pubmed: 27754465
J Biol Chem. 2002 Dec 20;277(51):49870-6
pubmed: 12351644
Nat Rev Mol Cell Biol. 2017 Jun;18(6):361-374
pubmed: 28356571
J Neurochem. 2019 Apr;149(2):231-241
pubmed: 30776097
J Biol Chem. 2005 Aug 19;280(33):29828-36
pubmed: 15923178
Clin Sci (Lond). 2019 Mar 19;133(6):763-776
pubmed: 30890654
Cells. 2020 Apr 15;9(4):
pubmed: 32326444
Biomolecules. 2019 Jul 27;9(8):
pubmed: 31357634
Sci Rep. 2019 Jul 26;9(1):10871
pubmed: 31350453
Cancer Sci. 2015 Nov;106(11):1544-53
pubmed: 26470851
Cancer Res. 2002 Jul 1;62(13):3729-35
pubmed: 12097282
Exp Mol Med. 2010 Dec 31;42(12):849-55
pubmed: 21072003

Auteurs

Norihiko Sasaki (N)

Research Team for Geriatric Medicine (Vascular Medicine), Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, Japan.

Masashi Toyoda (M)

Research Team for Geriatric Medicine (Vascular Medicine), Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, Japan.

Toshiyuki Ishiwata (T)

Division of Aging and Carcinogenesis, Research Team for Geriatric Pathology, Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH